Physician profile
Ann E Walker
NPI 1437451598
$5,446.62
in general payments reported to CMS, 2019-2025
25 companies · $2,071 in 2025
The $2,071 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.14 · 2022: $400 · 2023: $1,261 · 2024: $1,686 · 2025: $2,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,402 · Travel and Lodging: $1,729 · Education: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.41 |
| Travel and Lodging | $1,728.51 |
| Education | $887.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,627.35 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $840.37 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $339.30 | 2022-2025 | Dupixent |
| Harmony Biosciences LLC | $327.35 | 2022-2025 | Wakix |
| Grifols USA, LLC | $212.59 | 2022-2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $171.94 | 2022-2023 | |
| Astellas Pharma US INC | $162.63 | 2023-2024 | Cresemba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.44 | 2022-2024 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Genzyme Corporation | $75.96 | 2022-2025 | |
| United Therapeutics Corporation | $74.76 | 2022-2023 | Tyvaso, Orenitram |
| Amgen INC. | $73.39 | 2022-2025 | Tezspire, Tavneos |
| Takeda Pharmaceuticals U.S.A., INC. | $69.93 | 2023-2024 | Glassia |
| Insmed, INC. | $67.25 | 2025 | Arikayce |
| Glaxosmithkline, LLC. | $35.62 | 2024-2025 | Nucala |
| 3b Medical, INC. | $30.03 | 2025 | Luna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $29.72 | 2023-2024 | Uptravi, Opsumit |
| Philips North America LLC | $29.31 | 2022 | |
| Abbvie INC. | $28.14 | 2021 | |
| Axsome Therapeutics, INC. | $28.08 | 2022-2023 | Sunosi |
| Astrazeneca Pharmaceuticals Lp | $26.77 | 2023-2024 | Fasenra |
| Verona Pharma, INC. | $19.41 | 2025 | Ohtuvayre |
| Hospira, INC. | $17.57 | 2024 | |
| Baxter Healthcare | $17.53 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Hologic Sales and Service, LLC | $16.03 | 2024 | Omni Hysteroscope |
| Avadel Cns Pharmaceuticals, LLC | $14.15 | 2023 | Lumryz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.